Skip to content
CancerIndex

Publication

Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.

Authors not recorded

Pigment Cell Melanoma Res2014PMID 24495407stubpubmedProvenance
Source
PubMed
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-CIVIC-20260908-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Data not yet available

No abstract stored. Read on PubMed

Linked entities

Linked entities (6)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Validated 6

Curated evidence

Evidence citing this paper (4)

civicProvenance
Source
CIViC — Clinical Interpretation of Variants in Cancer
Dataset
CIViC evidence items
Version
civic-2026-09-08
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Evidence
expert curation
License
CC0 1.0
PMID
24495407
Run
ING-CIVIC-20260908-000001
Open at source CuratedShowing 1–4 of 4 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.
TherapyCancerTypeLevelDirection · significanceRating (1–5)StatusEvidenceSource
CDK4 R24C1
PalbociclibCutaneous MelanomaALIASPredictiveDSupports Sensitivity Response1accepted
EID1376

In a cohort of 143 patients with primary invasive melanoma, copy-number gain of CDK4 was observed (FISH) in 37% of cases. PD0332991 efficacy (proliferation assay) was assessed in a panel of 47 melanom… (full text at CIViC)

PMID 24495407 · Young et al., 2014 · Open in CIViC

civic
CDKN2A Loss1
PalbociclibCutaneous MelanomaALIASPredictiveDSupports Sensitivity Response3accepted
EID1375

In a cohort of 143 patients with primary invasive melanoma hemizygous or homozygous loss of CDKN2A was observed (FISH) in 56% of cases. PD0332991 efficacy (proliferation assay) was assessed in a panel… (full text at CIViC)

PMID 24495407 · Young et al., 2014 · Open in CIViC

civic
CDKN2A A20P1
PalbociclibMelanomaPredictiveDSupports Sensitivity Response—submitted
EID4524

In an in vitro study, a melanoma C052 cell line expressing CDKN2A A20P mutation (endogenous) demonstrated sensitivity to palbociclib treatment (GI50: 79nM). Sensitivity was determined by assessing cel… (full text at CIViC)

PMID 24495407 · Young et al., 2014 · Open in CIViC

civic
CDKN2A W110*1
PalbociclibMelanomaPredictiveDSupports Sensitivity Response—submitted
EID4523

In an in vitro study, a melanoma CHL1 cell line expressing CDKN2A W110* nonsense mutation (endogenous) demonstrated sensitivity to palbociclib treatment (GI50: 192nM). Sensitivity was determined by as… (full text at CIViC)

PMID 24495407 · Young et al., 2014 · Open in CIViC

civic